Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

執行長

員工

國家

上市

0 Comments

分享你的想法

FAQ

Ignyte Acquisition 今天的股價是多少？▼

PKBO 目前價格為 $0.02 USD，過去 24 小時上漲了 +0%。在圖表上更密切關注 Ignyte Acquisition 股價表現。

Ignyte Acquisition 的股票代號是什麼？▼

根據交易所不同，股票代號可能會有所差異。例如，在交易所，Ignyte Acquisition 的股票以代號 PKBO 進行交易。

Ignyte Acquisition 有多少名員工？▼

截至 April 02, 2026，公司共有 6 名員工。

Ignyte Acquisition 位於哪個產業？▼

Ignyte Acquisition從事於Professional, Scientific, and Technical Services產業。

Ignyte Acquisition 何時完成拆股？▼

Ignyte Acquisition 最近沒有進行任何拆股。